HIV Prevention in the United States:
Expanding the Impact
| Expanding the Impact | ||||
|---|---|---|---|---|
| Today’s Epidemic |
Proven Prevention Methods |
Progress To Date |
Challenges in HIV Prevention |
Future of HIV Prevention |
In the United States, it is estimated that prevention efforts have already averted more than 350,000 HIV infections.1 Since the height of the epidemic in the mid-1980s, the annual number of new HIV infections in the United States has been reduced by more than two-thirds, and recent scientific breakthroughs have equipped us with an unprecedented number of effective tools to prevent infection.2-6
CDC believes that maximizing the impact of these tools within the framework of a new approach called High-Impact Prevention offers more hope than ever before for reversing the U.S. HIV epidemic. Through High-Impact Prevention, CDC is working to advance the goals of the first National HIV/AIDS Strategy (NHAS) and to help ensure that HIV prevention efforts have the greatest possible impact.
- National HIV/AIDS Strategy (NHAS)
- High-Impact Prevention
- The Potential Impact of Prevention
- CDC’s HIV Prevention Activities: Four Focus Areas
Future of HIV Prevention (print version)
Key References:
1Farnham PG, Holtgrave DR, Sansom SL et al. Medical costs averted by HIV prevention efforts in the United States, 1991-2006. J Aquir Immune Defic Syndr 2010;54:565-67.
2CDC. Estimated HIV incidence among adults and adolescents in the United States, 2007–2010. HIV Surveillance Supplemental Report 2012;17(No. 4). Available at: http://www.cdc.gov/hiv/topics/surveillance/resources/reports/#supplemental. Published December 2012.
3Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. iPrEx Study Group. N Engl J Med 2010;363(27):2587-99.
4Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. The HPTN 052 Study Team. N Engl J Med 2011. DOI:10.1056/nejmoa1105243.
5Thigpen MC, Kebaabetswe PM, Smith DK, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 17-20, 2011. Rome. Abstract WELBC01.
6Baeten J. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP study. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 17-20, 2011. Rome. Abstract MOAX0106.
7The White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States. July 2010. Available at: http://www.whitehouse.gov/sites/default/files/uploads/NHAS.pdf. (Accessed June 25, 2012)
8CDC. Results of the expanded HIV testing initiative – 25 jurisdictions, United States, 2007-2010. MMWR 2011;60(24):805-10.
9Hutchinson AB, Farnham PG, Duffy N, et al. Return on public health investment: CDC’s Expanded HIV Testing Initiative. J Acquir Immune Defic Syndr 2012;59(3):281-86.
10Lasry A, Sansom S, Hicks K, et al. Allocating HIV prevention funds in the United States: recommendations from an optimization model. PLoSOne 2012;7(6):e37505. DOI: 10.1371/journal.pone.0037545.
11Hall HI, Green TA, Wolitski RJ et al. Estimated future HIV prevalence, incidence, and potential infections averted in the United States: a multiple scenario analysis. J Acquir Immune Defic Syndr 2010;55(2):271-76.
